Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4132933 | 1.00 | KMT2A (0.39) | KMT2AMEN1SMN1; SMN2ALDH1A1TAS1R3 | |
| SCHEMBL13936481 | 1.00 | KMT2A (0.39) | KMT2AMEN1SMN1; SMN2ALDH1A1TAS1R3 | |
| SCHEMBL4532895 | 1.00 | KMT2A (0.39) | KMT2AMEN1SMN1; SMN2ALDH1A1TAS1R3 | |
| SCHEMBL4532901 | 1.00 | KMT2A (0.39) | KMT2AMEN1SMN1; SMN2ALDH1A1TAS1R3 | |
| SCHEMBL1724063 | 0.85 | MEN1 (0.41) | KMT2AMEN1SMN1; SMN2ALDH1A1TAS1R3 | |
| SCHEMBL1724065 | 0.85 | MEN1 (0.41) | KMT2AMEN1SMN1; SMN2ALDH1A1TAS1R3 | |
| SCHEMBL13936482 | 0.85 | MEN1 (0.41) | KMT2AMEN1SMN1; SMN2ALDH1A1TAS1R3 | |
| SCHEMBL21178487 | 0.82 | LMNA (0.50) | KMT2AMEN1ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL1822267 | 0.80 | TTR (0.42) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL21183420 | 0.79 | LMNA (0.51) | KMT2AMEN1ALDH1A1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054460-A1 | Piperazine derivatives and methods of use | CHEN JIAN J | 2009-02-26 | — | — | US | disclosed |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7393852-B2 | Piperazine derivatives and methods of use | AMGEN INC. (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1656355-B1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1878728-A2 | Derivatives of piperazine and higher homologues thereof for the treatment of inflammation-related disorders | Amgen Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7199244-B2 | Cyclic amine derivatives and methods of use | AMGEN (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199244-B2 | Cyclic amine derivatives and methods of use | AMGEN (US) | 2007-04-03 | — | — | US | disclosed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | disclosed |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | AMGEN INC. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | KMT2A 4129/4885MEN1 3392/4885SMN1; SMN2 1190/4885 |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | LTC4S, PTGES, LTB4R2 | KMT2A 4129/4885MEN1 3392/4885SMN1; SMN2 1190/4885 |
| US-20090054460-A1 | Piperazine derivatives and methods of use | PTGES, PTGES2, PTGIS | KMT2A 2982/4885MEN1 4726/4885SMN1; SMN2 1545/4885 |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | ACHE, TNF, BCHE | KMT2A 3615/4885MEN1 3223/4885SMN1; SMN2 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.